Dual-mechanism anti-CD73 antibodies CR201 and CR202 targeting distinct domains for cancer immunotherapy - Scorecard - MDSpire

Dual-mechanism anti-CD73 antibodies CR201 and CR202 targeting distinct domains for cancer immunotherapy

  • By

  • Miao Zhang

  • Haibin Yuan

  • Xindi Pan

  • Xian Li

  • Zichen Wang

  • Shuping Zhang

  • Zhigang Gu

  • Biao Hu

  • Xuedong Qu

  • Qian Wang

  • Xiangguo Gu

  • Bo Wang

  • Yu Cao

  • Guilin Mu

  • Guangbo Kang

  • Ario de Marco

  • Xiangshan Zhou

  • He Huang

  • June 10, 2026

  • 0 min

Share

Clinical Scorecard: Monoclonal Antibodies CR201 and CR202: Targeting Different Domains of CD73 for Enhanced Cancer Immunotherapy

At a Glance

CategoryDetail
Condition
Key MechanismsInhibition of CD73 enzymatic activity and promotion of receptor internalization.
Target Population
Care Setting

Key Highlights

  • CR201 and CR202 are dual-mechanism anti-CD73 antibodies.
  • CR202 targets the N-terminal domain; CR201 targets the C-terminal domain.
  • Both antibodies restore T-cell proliferation and IFN-γ production.

Guideline-Based Recommendations

Diagnosis

  • Assess CD73 expression in tumors to identify potential candidates for therapy.

Management

  • Consider CR201 and CR202 for patients with CD73-overexpressing tumors.

Monitoring & Follow-up

  • Monitor T-cell activity and tumor response during treatment.

Risks

  • Potential for incomplete inhibition of soluble CD73 activity.

Patient & Prescribing Data

Patients with various cancers, including glioblastoma, pancreatic, colorectal, and non-small cell lung cancers.

CR201 and CR202 may enhance antitumor immune responses by targeting distinct domains of CD73.

Clinical Best Practices

    Related Resources & Content

    Original Source(s)

    Dual-mechanism anti-CD73 antibodies CR201 and CR202 targeting distinct domains for cancer immunotherapy

    • by Miao Zhang, Haibin Yuan, Xindi Pan, Xian Li, Zichen Wang, Shuping Zhang, Zhigang Gu, Biao Hu, Xuedong Qu, Qian Wang, Xiangguo Gu, Bo Wang, Yu Cao, Guilin Mu, Guangbo Kang, Ario de Marco, Xiangshan Zhou, He Huang

    • June 10, 2026

    Related Content

    Harnessing Vδ1+ T cells for next-generation immunotherapy: from mechanistic insights to clinical translation

    Multimodal treatment and long-term survival in a rare case of melanoma with pancreatic and splenic metastases: a case report and literature review

    Challenges and emerging strategies for genome-wide evaluation of loss of imprinting in cancer